Takeda Pharmaceutical Company Limited's latest marketcap:
As of 06/26/2025, Takeda Pharmaceutical Company Limited's market capitalization has reached $46.72 B. According to our data, Takeda Pharmaceutical Company Limited is the 466th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 46.72 B |
| Revenue (ttm) | 30.6 B |
| Net Income (ttm) | 720.73 M |
| Shares Out | 1.59 B |
| EPS (ttm) | 0.45 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 09/30/2024 |
| Earnings Date | 07/30/2025 |
Takeda Pharmaceutical Company Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/26/2025 | $46.72 B | 9.97% | 466 |
| 12/31/2024 | $42.13 B | -5.91% | 461 |
| 12/29/2023 | $44.78 B | -7.43% | 395 |
| 12/30/2022 | $48.37 B | 13.5% | 309 |
| 12/31/2021 | $42.62 B | -24.84% | 462 |
| 12/31/2020 | $56.7 B | -8.18% | 270 |
| 12/31/2019 | $61.76 B | 134.31% | 185 |
| 12/31/2018 | $26.36 B | -65.5% | 435 |
| 03/30/2017 | $76.41 B | 18.26% | 132 |
| 12/30/2016 | $64.61 B | -22.54% | 122 |
Company Profile
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global leader in the research, development, manufacturing, and marketing of pharmaceutical products. Headquartered in Tokyo, Japan, the company has been at the forefront of healthcare innovation since its founding in 1781.
Core Therapeutic Areas
Takeda specializes in delivering advanced treatments across several key medical fields, including:
- Gastroenterology
- Rare Diseases
- Plasma-Derived Therapies
- Immunology
- Oncology
- Neuroscience
Key Product Brands
Takeda offers a diverse portfolio of pharmaceutical products under well-known brands, such as:
- Entyvio
- Adcetris
- Vyvanse/Elvanse
- Trintellix
- QDENGA
- Alunbrig
- Ninlaro
- Livtencity
- Takhzyro
- Gammagard Liquid/Kiovig
Strategic Collaborations & Partnerships
Takeda actively engages in research collaborations and licensing agreements with leading biotech and pharmaceutical organizations, including:
- BioMarin
- GlaxoSmithKline
- Neurocrine Biosciences
- Denali Therapeutics
- Mirum Pharmaceuticals
- Teva Pharmaceutical Industries
- Arrowhead Pharmaceuticals
- Poseida Therapeutics
With a strong commitment to innovation, Takeda continues to expand its global footprint and deliver transformative healthcare solutions worldwide.
Frequently Asked Questions
-
What is Takeda Pharmaceutical Company Limited's (TAK) current market cap?As of 06/26/2025, Takeda Pharmaceutical Company Limited (including the parent company, if applicable) has an estimated market capitalization of $46.72 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Takeda Pharmaceutical Company Limited (TAK) rank globally by market cap?Takeda Pharmaceutical Company Limited global market capitalization ranking is approximately 466 as of 06/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.